Brief: CytRx to present data from global phase 2b clinical trial of aldoxorubicin
17/10/2014 11:00
Oct 17 (Reuters) - CytRx Corp CYTR.O : * To present data from global phase 2b clinical trial of aldoxorubicin in first-line soft tissue sarcoma at 2014 ctos annual meeting * Says trial has not yet reached necessary number of survival events to report on overall survival * Source text for Eikon ID:nPn1Y3z6m * Further company coverage CYTR.O ((Bangalore Newsroom; +1 646 223 8780))
Recent news on LadRx
See all newsBrief: Ladrx Issues 2024 Update To Shareholders
Brief: LadRx Completes Non-Dilutive Financing Transaction For Up To $11 Mln With Xoma Corporation
Brief: LadRx Intends To Apply To List Stock On Nasdaq Under Symbol 'LADX'
Brief: LadRx Announces Review Of Strategic Alternatives, Provides Corporate Updates
Brief: CytRx Highlights Orphazyme's Update On Productive Meeting With FDA Regarding Arimoclomol In Niemann-Pick Disease Type C